1037 GMT - Fevertree's partnership with Molson Coors in the U.S. represents a meaningful change in the U.K. mixer-maker's investment case, Goodbody analyst Fintan Ryan says in a note. On the positive side, Fevertree will receive cash up front to return to shareholders while Molson Coors will assume the operational costs and risks from executing the long-term growth potential of the brand in the U.S., the analyst says. However, Fevertree will also lose direct control of its largest market, a region where the company still is performing well and has the clearest strategy for market share growth, the analyst adds. Shares are up almost 25% at 814.0 pence, on track for their biggest intraday rise. (michael.susin@wsj.com)
(END) Dow Jones Newswires
January 30, 2025 05:39 ET (10:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.